W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

25 July, 2024

Position of the Transparency Council – Cablivi (caplacizumab)

25 July, 2024

Position of the Transparency Council – Ilaris (canakinumab)

25 July, 2024

Position of the Transparency Council – Tecentriq (atezolizumab)

25 July, 2024

Position of the Transparency Council – Fintepla (fenfluramine)

25 July, 2024

Position of the Transparency Council – Enhertu (trastuzumab deruxtecan)

25 July, 2024

Communication of the meeting of Transparency Council No. 31/2024 on 22 July 2024

24 July, 2024

Recommendation of the President – Agamree (vamorolone) in the indication of Becker muscular dystrophy

24 July, 2024

Recommendation of the President – Agamree (vamorolone) in the indication Duchenne muscular dystrophy

24 July, 2024

The Transparency Council meeting 32/2024 on 29 July 2024

22 July, 2024

Communication of the meeting of Tariff Council meeting on 18 July 2024

19 July, 2024

Recommendation of the President – Kanuma (sebelipaza alfa)

18 July, 2024

Communication of the meeting of Transparency Council No. 30/2024 on 15 July 2024

18 July, 2024

Opinion of the Transparency Council – filgrastym

18 July, 2024

Opinion of the President – type 2 diabetes prevention program for Pajeczan County residents aged 45-64 years for 2024-2027

18 July, 2024

Opinion of the President – hearing screening program for students in the first grade of elementary schools located in the city of Bedzin for 2025-2027

17 July, 2024

Position of the Transparency Council – Agamree (vamorolone)

17 July, 2024

Position of the Transparency Council – Agamree (vamorolone)

17 July, 2024

Position of the Transparency Council – Lynparza (olaparib)

17 July, 2024

Position of the Transparency Council – Hemlibra (emicizumab)

17 July, 2024

Position of the Transparency Council – Opdivo (nivolumab)

17 July, 2024

Position of the Transparency Council – Cabometyx (cabozantinib)

17 July, 2024

The Transparency Council meeting 31/2024 on 22 July 2024

12 July, 2024

Recommendation of the President – Zynlonta (loncastuximab tesirine)

12 July, 2024

Recommendation of the President – prevention of necrotizing enterocolitis (NEC) in premature infants with birth weight less than 1,500 g using food for special medical use – a three-strain probiotic product that meets the criteria of ESPGHAN recommendation

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑